Skip to main content

Remote Job Finders (RJF)

Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push

Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for treating schizophrenia with its 2024 approval.

Biopharma layoffs rise YOY in October but sharply trend down for 2026

October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025. Still, it’s highly unlikely 2026 layoffs will come close to matching the downsizing seen last year.
Scroll to top